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Abstract
Recent studies suggest that normal tissue radiosensitivity is influenced by single nucleotide polymorphisms (SNPs) in certain
genes. In order to seek a confirmation of these findings, this study investigated SNPs in genes TGFB1 (position K509, codon 10
and codon 25), SOD2 (codon 16), XRCC1 (codon 399), XRCC3 (codon 241), APEX (codon 148) and ATM (codon 1853) in 26 breast
cancer patients with marked changes in breast appearance after radiotherapy and 26 matched controls. Statistically significant
associations were found between the TGFB1 codon 10 Pro allele (PZ0.005) as well as the TGFB1 position K509 T allele (PZ
0.018) and increased risk of altered breast appearance. No significant associations were found for the remaining SNPs.
q 2005 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 75 (2005) 18–21.
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tissue complications prior to cancer treatment has been a
long sought goal in radiobiology. Currently, increasing
efforts are made to investigate whether clinical normal
tissue radiosensitivity is influenced by genetic germline
variation [1,6]. A recently published study, based on a cohort
of 41 Danish breast cancer patients given post-mastectomy
radiotherapy, has indicated a possible association between
selected single nucleotide polymorphisms (SNPs) and the risk
of subcutaneous fibrosis after radiotherapy [2]. According to
this study, the fibrosis risk was dependent on the number of
‘risk alleles’ possessed at the polymorphic sites TGFB1
position K509 and codon 10, XRCC3 codon 241, XRCC1 codon
399 and SOD2 codon 16. A borderline significant association
was observed for the TGFB1 codon 25 SNP whereas no
obvious correlation was found for the APEX codon 148 SNP. In
addition, the same patient cohort has lately been subjected
to an investigation in which the ATM gene was systematically
screened for genetic variation [15]. This study provided
indications that the ATM codon 1853 Asp/Asn (G 5557 A) SNP
may also affect risk of radiation induced fibrosis. Only a very
limited number of other studies have addressed the
influence of these SNPs upon normal tissue radiosensitivity
[4,9,10,12,14]. In 2003, Quarmby et al. established signifi-
cant associations between the TGFB1 position K509
and codon 10 SNPs and risk of subcutaneous fibrosis after0167-8140/$ - see front matter q 2005 Elsevier Ireland Ltd. All rights resepost-lumpectomy radiotherapy for breast cancer [14].
Angele et al. demonstrated an association between the
ATM codon 1853 Asn/Asn genotype and enhanced risk of
various adverse reactions after radiotherapy for breast
cancer [4]. Within the same patient cohort indications
were found that the XRCC1 codon 399 SNP in combination
with the relatively uncommon codon 194 SNP may also affect
normal tissue radiosensitivity [12]. In 1998, a relatively small
study reported a moderate overrepresentation of the ATM
codon 1853 Asn allele among prostate cancer patients with
severe late effects [10]. In order to seek a confirmation of
the results obtained in the Danish patient cohort, the
present study applied the analysis of the same SNPs to an
independent patient cohort of women given radiotherapy
after breast preserving surgery for breast cancer [18].
Subsets of this cohort have earlier been used for studies
addressing the influence of truncating ATM mutations and
SOD2 SNPs on normal tissue radiosensitivity [9,16]. In both
studies, no significant associations were found between the
investigated genetic variations and risk of altered breast
appearance after radiotherapy. However, since the original
SOD2 study differed slightly from the present with regard
to patient selection and statistical analysis, the SOD2 codon
16 SNP (also referred to as SOD2 Ala-9Val) was also included
in the present investigation. Furthermore, a relatively
rare polymorphism designated ATM codon 1853 Asp/Valrved. doi:10.1016/j.radonc.2004.12.012
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5557 A) SNP. Since this polymorphism may potentially alter
the amino acid incorporated at codon 1853, it was assessed
as well.Material and methods
The patients included in this study were given radio-
therapy after breast preserving surgery for early stage breast
cancer as part of a large radiotherapy fractionation trial at
the Royal Marsden Hospital, Sutton and the Gloucestershire
Oncology Centre, Cheltenham, UK. Patient characteristics,
radiotherapy regimens, definition and assessment of end-
points have been reported in detail [18] and are therefore
only described briefly here. Between 1986 and 1994, 935
patients were enrolled in the trial. Of these patients, 855
had baseline post-operative photographs of the breasts
taken under standard conditions, which were repeated
annually for 5 years. Changes in breast appearance com-
pared to the post-surgical baseline photograph were scored
on a three-point graded scale based on change in breast size
and/or shape. Assessments were performed by three
independent observers blind to patient identity, randomised
radiotherapy dose and year of follow-up. Cases were defined
as individuals developing marked changes (grade 2) at any
time between 1 and 5 years after radiotherapy, or moderate
changes (grade 1) scored for at least three consecutive
years. Control subjects were defined as women with no
change (grade 0) at the same time as the case experienced a
reaction. From 104 of these patients (39 cases and 65
controls), fibroblast culture has previously been established
[13]. For the purpose of the present study, 26 case–control
pairs with accessible biological material and a perfect match
regarding breast anatomy and treatment characteristics
(breast size, surgical deficit, radiotherapy dose schedule,
radiotherapy boost dose, tangential field separation, central
lung distance and systemic therapy) could be identified.Table 1
Overview of assessed SNPs, primers and probes
SNP PCR primers
Sense A
TGFB1 pos. K509 C/T
(promoter)
AAG GAG AGC AAT TCT TAC
AGG TGT CT
G
TGFB1 codon 10 Leu/Pro
(T 869 C)
GCG CTC TCG GCA GTG C C
TGFB1 codon 25 Arg/Pro
(G 915 C)
CTG CTA CCG CTG CTG TGG
CTA
T
SOD2 codon 16 Val/Ala
(T 47 C)
CTG CGT AGA CGG TCC CG T
XRCC1 codon 399 Arg/Gln
(G 28152 A)
CGC ATC GTG CGT AAG GAG G
XRCC3 codon 241 Thr/Met
(C 18067 T)
GAT GCA CAG CAC AGG GCT C G
APEX codon 148 Asp/Glu
(T 2107 G)
CTA TTG ATG CCT AAT GCC TGA
ACT C
T
ATM codon 1853 Asp/Asn
(G 5557 A)
GAC TTT TGT CAG ACT GTA CTT
CCA TAC TTG
T
A
ATM codon 1853 Asp/Val
(A 5558 T)
GAC TTT TGT CAG ACT GTA CTT
CCA TAC TTG
T
ASeven pairs were given 50.0 Gy in 25 fractions, 13 pairs were
given 42.9 Gy in 13 fractions whereas 6 pairs received
39.0 Gy in 13 fractions.
DNA was extracted from cultured fibroblasts using the ABI
Prisme 6100 Nucleic Acid PrepStation and the provided
reagents according to the manufactures protocols (Applied
Biosystems, Foster City, USA). From three patients, fibro-
blast culture was no longer accessible and DNA was isolated
from fresh frozen lymphocytes or subcutaneous biopsies.
The TGFB1 position K509 and codon 10 SNPs were assessed
by TaqManw based real time PCR on the ABI Prismw 7000
Sequence Detection System (Applied Biosystems, Foster
City, USA). Primers and probes are listed in Table 1. For
the remaining SNPs relevant DNA fragments were amplified
by 35 rounds of thermal cycling (95 8C for 30 s, 60 8C for 30 s
and 72 8C for 30 s) using Amplitaq Gold polymerase (Applied
Biosystems, Foster City, USA) and standard reaction con-
ditions. PCR products were purified using a 4% agarose gel
and the QIA-quick Gel Extraction Kit (Qiagen, Germany). The
SNP genotypes were assessed by ‘single nucleotide primer
extension’ using the ABI Prismw SNaPshote Multiplex kit
on an ABI 310 genetic analyzer (Applied Biosystems, Foster
City, USA). PCR primers and extension primers are listed in
Table 1. The analysis was conducted blind to patient
identity, treatment characteristics, case–control status,
etc. Redundant tests were carried out to assure assay
reproducibility. For each SNP, a putative risk allele was
defined according to the results obtained in the SNP studies
previously conducted in the 41 Danish breast cancer patients
[2,15]. With respect to the APEX codon 148 SNP, the minority
allele (Glu) was arbitrarily chosen as putative risk allele. At
each polymorphic site, the number of putative risk alleles
could be 0, 1 or 2. The matched pairs were analysed as to
whether the index case had a higher, lower or equivalent
number of risk alleles compared to the control. A Wilcoxon
signed ranks test for paired data was used to evaluate
whether the distribution of number of risk alleles wereTaqManw probes/extension
primers
ntisense
CC TCC GGA GGG TGT CA VIC-CCA TCC CTC AGG TGT,
6FAM-CAT CCT TCA GGT GTC
CA GGC GTC AGC ACC AGT A VIC-AGC AGC GGC AGC A,
6FAM-CAG CAG CAG CAG C
CC GCT TCA CCA GCT CCA (T)19 GGT GCT GAC GCC TGG CC
GA TGT GAG GTT CCA GGG C GGA GCC CAG ATA CCC CAA A
GA CCA CCT GTG TTC TCC G GGC GGC TGC CCT CCC
GT CAT CGA CTC GGT GGC TGC TCA GCT CAC GCA GC
TC AGC CAC AAT CAC CCG (T)5 ATT CTG TTT CAT TTC TAT
AGG CGA
CC CTG AAC ATG TGT AGA
AG CAG
CTT GAT TCA TGA TAT TTT ACT
CCA A
CC CTG AAC ATG TGT AGA
AG CAG
CAG ATT TCT CCA TGA TTC ATT
TGT A
Table 2
Putative risk alleles and distribution of pairs as to the number of risk alleles in the case compared to the matched control
SNP Putative
risk allele
Distribution of pairs as to no. of risk alleles in the case compared to the
matched control
Wilcoxon signed
ranks test P-value
CaseOcontrol Case!control CaseZcontrol
TGFB1 pos. K509 T 11 3 12 0.018
TGFB1 codon 10 Pro 11 1 14 0.005
TGFB1 codon 25 Pro 3 3 20 O0.99
SOD2 codon 16 Ala 8 8 10 0.82
XRCC1 codon 399 Arg 5 4 17 0.67
XRCC3 codon 241 Thr 7 9 10 0.67
APEX codon 148 Glu 7 8 11 0.64
ATM codon 1853 Gln 7 4 15 0.48
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cases and controls (Table 2).Results and discussion
The study demonstrated a significant association between
the TGFB1 codon 10 Leu/Pro SNP and risk of altered breast
appearance after radiotherapy. In 11 pairs, the index case
had a higher number of Pro alleles than the matched control,
whereas only one pair was characterized by the opposite
finding (PZ0.005). A statistically significant association was
also found for the TGFB1 position K509 C/T SNP. In 11 pairs,
the index case had a higher number of T alleles than the
matched control whereas in only three pairs, the matched
control had a higher number of T alleles than the case
(PZ0.018). For the remaining SNPs, the study did not
provide any significant associations with risk of radiotherapy
complications (Table 2). No patients had the ATM codon
1853 Asp/Val (A 5558 T) polymorphism.
Interestingly, both previously published studies addressing
the influence of TGFB1 SNPs on clinical radiosensitivity
established significant associations between the TGFB1
codon 10 Pro allele as well as the position K509 T allele and
increased risk of radiation induced late complications [2,14].
Taking the present study into account, consistent evidence is
accumulating that the risk of late normal tissue morbidity
after radiotherapy is modulated by the TGFB1 SNP genotype.
A genetic linkage pattern has previously been described for
the TGFB1 SNPs [3,5,17]. Even though the functional impact
of the individual SNPs remain to be elucidated, the present
study seems to indicate that the correlation observed for the
TGFB1 position K509 SNP could be a result of genetic linkage
with the codon 10 SNP. This assumption is supported by a
recent in vitro study suggesting that the TGFB1 codon 10 SNP
has a considerable impact on the TGFb-1 secretion rate [8].
For the remaining SNPs, the present study did not confirm the
associations previously observed in the Danish breast cancer
patient cohort [2,15]. This discrepancy may be attributed to
several factors. Due to small sample size, the present study
provided very limited statistical power to rule out a modest
effect of the assessed SNPs. This problem was particularly
pronounced for relatively uncommon polymorphisms such as
the ATM codon 1853 and TGFB1 codon 25 SNPs. Regarding the
ATM codon 1853 SNP, seven pairs were identified in whichthe index case had a higher number of Gln alleles than the
matched control. Four pairs were characterized by the
opposite finding (Table 2). Even though this skewing in the
distribution was far from reaching statistical significance, it
might be of interest since the codon 1853 Asn allele has
previously been linked to increased risk of radiation induced
normal tissue reactions [4,15]. In the present investigation,
the primary endpoint was (grade 1 or 2) alteration of breast
appearance assessed by serial photography [16,18]. In
contrast, the 41 Danish patients were evaluated for (grade
3) subcutaneous induration by manual palpation [2]. From a
biological point of view these endpoints are hardly equival-
ent. In the two studies, the length of follow-up was within the
same range. However, as demonstrated in two recent papers,
factors related to the kinetics of late normal tissue reactions
may still hinder the detection of associations, especially for
genetic alterations with only moderate impact on normal
tissue complication risk [7,11].
In conclusion, the present study demonstrated significant
associations between the TGFB1 codon 10 Pro allele as well as
the TGFB1 position K509 T allele and risk of altered breast
appearance after radiotherapy. The remaining associations
previously observed in the cohort of 41 Danish breast cancer
patients could not be confirmed. These findings should
encourage further efforts to unravel the genetic basis of
clinical radiosensitivity and emphasize the need for large
studies that provide sufficient statistical power to detect and
quantify rather small differences in radiosensitivity.Acknowledgements
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